Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies

被引：0
|
作者：
Xenofon Baraliakos
Filip Van den Bosch
Pedro M. Machado
Lianne S. Gensler
Helena Marzo-Ortega
Bintu Sherif
Erhard Quebe-Fehling
Brian Porter
Corine Gaillez
Atul Deodhar
机构：
[1] Ruhr-University Bochum,Rheumazentrum Ruhrgebiet Herne
[2] Ghent University,Department of Internal Medicine and Pediatrics
[3] VIB Center for Inflammation Research,Department of Rheumatology
[4] University College London Hospitals NHS Foundation Trust,Department of Rheumatology, Northwick Park Hospital
[5] London North West University Healthcare NHS Trust,Centre for Rheumatology and Department of Neuromuscular Diseases
[6] University College London,Department of Medicine/Rheumatology
[7] University of California,NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds Institute of Rheumatic and Musculoskeletal Medicine
[8] San Francisco,undefined
[9] University of Leeds,undefined
[10] RTI Health Solutions,undefined
[11] Novartis Pharma AG,undefined
[12] Novartis Pharmaceuticals Corporation,undefined
[13] Oregon Health and Science University,undefined
来源：
Rheumatology and Therapy | 2021年 / 8卷
关键词：
Ankylosing spondylitis; Axial spondyloarthritis; Biologics; Interleukin-17; Low disease activity; Patient-reported outcomes; Remission; Secukinumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：273 / 288
页数：15
相关论文
共 50 条
  • [41] REDUCTION IN FATIGUE IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS ARE SUSTAINED OVER 2 YEARS: LONG-TERM RESULTS OF TWO PHASE 3 STUDIES WITH SECUKINUMAB
    Gossec, L.
    Kvien, T. K.
    Conaghan, P. G.
    Ostergaard, M.
    Canete, J.
    Gaillez, C.
    Mpofu, S.
    Davenport, E.
    Jugl, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 351 - 351
  • [42] Cardio-metabolic effects of long-term treatment with secukinumab in psoriatic arthritis and ankylosing spondylitis patients: Pooled 3 year analysis
    McInnes, Iain B.
    Gladman, Dafna D.
    Deodhar, Atul A.
    Miceli-Richard, Corinne
    Nash, Peter
    Sattar, Naveed
    Mehta, Nehal N.
    Wang, Jianyuan
    Pricop, Luminita
    di Comite, Gabriele
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB33 - AB33
  • [43] SECUKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ANKYLOSING SPONDYLITIS, IRRESPECTIVE OF TIME SINCE FIRST DIAGNOSIS: POOLED RESULTS FROM THE SECUKINUMAB PHASE 3 TRIAL PROGRAM
    Deodhar, Atul
    Boonen, Annelies
    Ferraccioli, Gianfranco
    van den Bosch, Filip
    Martinez, David
    Porter, Brian
    Shete, Abhijit
    Gilloteau, Isabelle
    Yocolly, Aurore
    Strand, Vibeke
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 878 - 879
  • [44] THE COURSE OF ESTABLISHED ANKYLOSING-SPONDYLITIS AND THE EFFECTS OF SULFASALAZINE OVER 3 YEARS
    KIRWAN, JR
    EDWARDS, A
    HUITFELDT, B
    THOMPSON, PW
    CURREY, HLF
    BRITISH JOURNAL OF RHEUMATOLOGY, 1992, 31 : 82 - 82
  • [45] THE COURSE OF ESTABLISHED ANKYLOSING-SPONDYLITIS AND THE EFFECTS OF SULFASALAZINE OVER 3 YEARS
    KIRWAN, J
    EDWARDS, A
    HUITFELDT, B
    THOMPSON, P
    CURREY, H
    BRITISH JOURNAL OF RHEUMATOLOGY, 1993, 32 (08): : 729 - 733
  • [46] SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 STUDY
    Pavelka, K.
    Kivitz, A. J.
    Blanco, R.
    Maradiaga, M.
    Tahir, H.
    Slade, A.
    Wang, Y.
    Rohrer, S.
    Porter, B.
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S107 - S108
  • [47] Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 2-Year Results from a Phase 3 Study
    Pavelka, Karel
    Kivitz, Alan J.
    Dokoupilova, Eva
    Blanco, Ricardo
    Maradiaga, Marco
    Tahir, Hasan
    Slade, Alan
    Wang, Yi
    Rohrer, Susanne
    Porter, Brian
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [48] SECUKINUMAB SUSTAINS INDIVIDUAL CLINICAL RESPONSES OVER TIME IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS: 2-YEAR RESULTS FROM A PHASE 3 TRIAL, MEASURE 2
    Baraliakos, X.
    Schiff, M.
    Pavelka, K.
    Widmer, A.
    Porter, B.
    Gaillez, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 358 - 358
  • [49] SECUKINUMAB PROVIDES RAPID AND SUSTAINED RESOLUTION OF ENTHESITIS IN PSORIATIC ARTHRITIS PATIENTS: POOLED ANALYSIS OF TWO PHASE 3 STUDIES, FUTURE 2 AND FUTURE 3
    Coates, Laura C.
    McGonagle, Dennis
    Schett, Georg
    Mease, Philip J.
    Quebe-Fehling, Erhard
    Asquith, Darren L.
    Rasouliyan, Lawrence
    Mpofu, Shepard
    Gaillez, Corine
    RHEUMATOLOGY, 2019, 58 : 149 - 149
  • [50] SECUKINUMAB PROVIDES CLINICAL IMPROVEMENTS IN PATIENTS WITH ACTIVE OLIGOARTICULAR PSORIATIC ARTHRITIS: RESULTS FROM A POOLED ANALYSIS OF FIVE PHASE 3 STUDIES
    Coates, Laura C.
    Ogdie, Alexis
    Gladman, Dafna D.
    Pournara, Effie
    Meng, Xiangyi
    Parikh, Bhumik
    Mease, Philip J.
    RHEUMATOLOGY, 2022, 61
12345